• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 4 - Considering the Costs of Hepatitis C Treatment

Article

While some patients and physicians are not aware of the costs of care, others are concerned about whether they can afford treatment options at all. Dr Miller describes some of the major steps to the incremental benefits and incremental costs incurred by new agents.

While some patients and physicians are not aware of the costs of care, others are concerned about whether they can afford treatment options at all. Dr Miller describes some of the major steps to the incremental benefits and incremental costs incurred by new agents.

“We’re recommending that actually, when these patients are screened and are positive, that they actually get appropriately staged by a hepatologist. This has become much more complex, and even though the agents are orally available now—which means many more primary care doctors may want to attempt to treat these patients—I think proper identification of which patients should be treated, and making sure that they’re really being worked up appropriately and tracked appropriately, is going to be crucial,” he says. “This is becoming a much more complex disease to treat. The great news is that it’s also becoming much more treatable. We’re recommending to our clients that they encourage evaluation by a hepatologist.”

Dr Wilson suggests that new agents add tremendous value, especially when compared to other treatments historically. The cost equation, however, can be overwhelming.

The panelists go on to discuss how sofosbuvir and simeprevir showed improvement in hard-to-treat patients, or those who failed to showed improvement with interferon-based treatment. Outcomes of these new treatments can be tremendous, but how these patients can receive treatment may be the real challenge.

Related Videos
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
James Robinson, PhD, MPH, University of California, Berkeley
James Robinson, PhD, MPH, University of California, Berkeley
James Robinson, PhD, MPH, University of California, Berkeley
Carrie Kozlowski
James Robinson, PhD, MPH, University of California, Berkeley
Carrie Kozlowski, OT, MBA
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Carrie Kozlowski, OT, MBA
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.